home / stock / ocup / ocup quote
Last: | $1.61 |
---|---|
Change Percent: | 4.89% |
Open: | $1.55 |
Close: | $1.535 |
High: | $1.61 |
Low: | $1.55 |
Volume: | 36,611 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.61 | $1.55 | $1.535 | $1.61 | $1.55 | 36,611 | 04-26-2024 |
$1.535 | $1.52 | $1.535 | $1.5567 | $1.5 | 109,604 | 04-25-2024 |
$1.53 | $1.52 | $1.53 | $1.5623 | $1.5 | 89,829 | 04-24-2024 |
$1.54 | $1.51 | $1.54 | $1.58 | $1.51 | 140,451 | 04-23-2024 |
$1.51 | $1.64 | $1.51 | $1.64 | $1.5 | 379,231 | 04-22-2024 |
$1.655 | $1.67 | $1.655 | $1.71 | $1.59 | 237,605 | 04-19-2024 |
$1.67 | $1.77 | $1.67 | $1.78 | $1.67 | 239,627 | 04-18-2024 |
$1.74 | $1.74 | $1.74 | $1.775 | $1.7394 | 92,408 | 04-17-2024 |
$1.74 | $1.74 | $1.74 | $1.7899 | $1.7 | 113,769 | 04-16-2024 |
$1.76 | $1.86 | $1.76 | $1.86 | $1.74 | 199,447 | 04-15-2024 |
$1.84 | $1.82 | $1.84 | $1.89 | $1.71 | 470,172 | 04-12-2024 |
$1.79 | $1.84 | $1.79 | $1.87 | $1.77 | 235,205 | 04-11-2024 |
$1.86 | $1.9 | $1.86 | $1.91 | $1.83 | 173,750 | 04-10-2024 |
$1.86 | $1.83 | $1.86 | $1.888 | $1.83 | 95,428 | 04-09-2024 |
$1.83 | $1.93 | $1.83 | $1.93 | $1.83 | 284,744 | 04-08-2024 |
$1.91 | $1.93 | $1.91 | $1.94 | $1.83 | 272,560 | 04-05-2024 |
$1.88 | $2 | $1.88 | $2.04 | $1.855 | 340,415 | 04-04-2024 |
$1.94 | $2.14 | $1.94 | $2.2199 | $1.9 | 476,813 | 04-03-2024 |
$2.18 | $2.24 | $2.18 | $2.34 | $2.14 | 724,199 | 04-02-2024 |
$2.23 | $2.02 | $2.23 | $2.23 | $2.02 | 702,330 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ocuphire Pharma Inc Com Company Name:
OCUP Stock Symbol:
NASDAQ Market:
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, ...
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for t...
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. comme...